Table 4 Distribution of the patients studied according to treatments at baseline in each BCLC grade.
From: ALBI-sarcopenia score as a predictor of treatment outcomes in hepatocellular carcinoma
Treatment at baseline | Total (n = 262) | BCLCA (n = 74) | BCLCB (n = 142) | BCLCC (n = 46) |
|---|---|---|---|---|
RFA | 40 (15.3%) | 28 (37.8%) | 12 (8.5%) | 0 (0.0%) |
PEI | 15 (5.7%) | 4 (5.4%) | 11 (7.7%) | 0 (0.0%) |
Microwave | 24 (9.2%) | 17 (23.0%) | 7 (4.9%) | 0 (0.0%) |
TACE | 108 (41.2%) | 10 (13.5%) | 98 (69.0%) | 0 (0.0%) |
Resection | 15 (5.7%) | 15 (20.3%) | 0 (0.0%) | 0 (0.0%) |
BSC | 15 (5.7%) | 0 (0.0%) | 0 (0.0%) | 15 (32.6%) |
Sorafenib | 31 (11.8%) | 0 (0.0%) | 0 (0.0%) | 31 (67.4%) |
Sorafenib combined | 1 (0.4%) | 0 (0.0%) | 1 (0.7%) | 0 (0.0%) |
Combined intervention | 13 (5%) | 0 (0%) | 13 (9.2%) | 0 (0%) |
